Showing results (261-270 of 933) with videos related to
Sort By:
Pageof 94
British Journal of Haematology|January 18, 2006
The role of gemtuzumab ozogamicin in acute leukaemia therapyApostolia-Maria Tsimberidou, Francis J Giles, Elihu Estey, et al.Cancer|March 29, 2002
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemiaJorge Cortes, Deborah Thomas, Adan Rios, et al.Blood|September 5, 2009
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-upRavin J Garg, Hagop Kantarjian, Susan O'Brien, et al.Cancer|March 21, 2009
Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapyRavin Garg, Hagop Kantarjian, Deborah Thomas, et al.Cancer|June 24, 2010
Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimenDeborah Thomas, Susan O'Brien, Stefan Faderl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic responseHagop M Kantarjian, Jianqin Shan, Daniel Jones, et al.Cancer|January 27, 2010
Adult acute lymphoblastic leukemia: concepts and strategiesStefan Faderl, Susan O'Brien, Ching-Hon Pui, et al.Cancer|March 29, 2002
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemiaMoshe Talpaz, Ashok Rakhit, Karen Rittweger, et al.Haematologica|May 27, 2014
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletionPaolo Strati, Michael J Keating, Susan M O'Brien, et al.Pageof 94